Survival benefit with regional anticoagulation with citrate in CRRT: the end of a myth?

of K/DOQI targets of mineral metabolism in Canada. Nephrol Dial Transplant 2011; 26: 156–163 6. Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578–589 7. Vervloet M, Bencova V, Malberti F et al. “Real-world” use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO Observational Study. Clin Nephrol 2010; 74: 198–208 8. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76: S1–S130 9. Manns BJ, Hodsman A, Zimmerman DL et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKDMineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2009; 55: 800–812 10. Uhlig K, Berns JS, Kestenbaum B et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2009; 55: 773–799 11. Goldsmith DJ, Covic A, Fouque D et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 25: 3823–3831